{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=De-escalated+Treatment&page=2",
    "query": {
      "intervention": "De-escalated Treatment",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 101,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=De-escalated+Treatment&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=De-escalated+Treatment&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T08:11:55.196Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06318871",
      "title": "Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Renal Carcinoma",
        "Renal Cell Carcinoma",
        "Urothelial Carcinoma",
        "Chromophobe Renal Cell Carcinoma",
        "Translocation Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cytokine Induced Memory-like Natural Killer (CIML NK) Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interleukin-2 (IL-2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2024-08-28",
      "completion_date": "2031-07-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-10-02T08:11:55.196Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06318871"
    },
    {
      "nct_id": "NCT01537042",
      "title": "A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Restless Legs Syndrome",
        "End-Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Rotigotine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB BIOSCIENCES GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2012-04",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2014-11-03",
      "last_synced_at": "2026-10-02T08:11:55.196Z",
      "location_count": 6,
      "location_summary": "Brandon, Florida • Newton, Massachusetts • West Seneca, New York + 3 more",
      "locations": [
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Newton",
          "state": "Massachusetts"
        },
        {
          "city": "West Seneca",
          "state": "New York"
        },
        {
          "city": "Dublin",
          "state": "Ohio"
        },
        {
          "city": "West Chester",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01537042"
    },
    {
      "nct_id": "NCT05293626",
      "title": "Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leber Hereditary Optic Neuropathy (LHON)"
      ],
      "interventions": [
        {
          "name": "NR082 Injection",
          "type": "DRUG"
        },
        {
          "name": "Injection needle",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Neurophth Therapeutics Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2023-05-22",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2024-09-04",
      "last_synced_at": "2026-10-02T08:11:55.196Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05293626"
    },
    {
      "nct_id": "NCT01044966",
      "title": "A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Glioma",
        "Astrocytoma",
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "ITV DepoCyt + Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 12,
      "start_date": "2009-09",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2019-02-12",
      "last_synced_at": "2026-10-02T08:11:55.196Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01044966"
    },
    {
      "nct_id": "NCT01677741",
      "title": "A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Brain"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Months to 17 Years"
      },
      "enrollment_count": 85,
      "start_date": "2013-05-23",
      "completion_date": "2020-12-04",
      "has_results": true,
      "last_update_posted_date": "2021-11-24",
      "last_synced_at": "2026-10-02T08:11:55.196Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Orange, California • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01677741"
    },
    {
      "nct_id": "NCT02340117",
      "title": "Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "SGT-53",
          "type": "GENETIC"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "SynerGene Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2015-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-05-30",
      "last_synced_at": "2026-10-02T08:11:55.196Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02340117"
    },
    {
      "nct_id": "NCT06835387",
      "title": "Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Bowel Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Nanoliposomal irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "5 fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tiago Biachi de Castria",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2025-06-30",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-02T08:11:55.196Z",
      "location_count": 7,
      "location_summary": "Tampa, Florida • Chicago, Illinois • Fort Wayne, Indiana + 4 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06835387"
    },
    {
      "nct_id": "NCT03328104",
      "title": "Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoblastic Leukemia",
        "Lymphoblastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Nelarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "2 Years to 29 Years"
      },
      "enrollment_count": 8,
      "start_date": "2018-07-24",
      "completion_date": "2023-06-29",
      "has_results": false,
      "last_update_posted_date": "2023-07-21",
      "last_synced_at": "2026-10-02T08:11:55.196Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • New York, New York • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03328104"
    },
    {
      "nct_id": "NCT01716195",
      "title": "Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Induction Chemotherapy followed by Response Adapted Chemoradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2012-10",
      "completion_date": "2020-10-01",
      "has_results": true,
      "last_update_posted_date": "2021-02-26",
      "last_synced_at": "2026-10-02T08:11:55.196Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01716195"
    },
    {
      "nct_id": "NCT05263050",
      "title": "Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Renal Cell Carcinoma",
        "Clear-cell Metastatic Renal Cell Carcinoma",
        "Neuroendocrine Tumors",
        "Carcinoid Tumor"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2022-01-21",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-02T08:11:55.196Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05263050"
    }
  ]
}